NTRK1 rearrangement in colorectal cancer patients: Evidence for actionable target using patient-derived tumor cell line

Oncotarget

Volumn 6, Issue 36, 2015, Pages 39028-39035

  Lee, Su Jin ^a   Li, Gang Gary ^b   Kim, Seung Tae ^a   Hong, Min Eui ^a   Jang, Jiryeon ^a   Yoon, Nara ^a   Ahn, Soo Min ^a   Murphy, Danielle ^b   Christiansen, Jason ^b   Wei, Ge ^b   Hornby, Zachary ^b   Lee, Dong Woo ^c   Park, Joon Oh ^a   Park, Young Suk ^a   Lim, Ho Yeong ^a   Hong, Sung No ^a   Kim, Seok Hyeong ^a   Kang, Won Ki ^a   Park, Keunchil ^a   Park, Woong Yang ^c   Kim, Kyoung Mee ^a   Lee, Jeeyun ^a   more..

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Ignyta   (United States)

^c Samsung Advanced Institute of Technology (SAIT)   (South Korea)

Author keywords

Colorectal cancer; NTRK1 rearrangement; TRKA immunohistochemistry

Indexed keywords

COMPLEMENTARY DNA; ENTRECTINIB; PROTEIN TYROSINE KINASE A; BENZAMIDE DERIVATIVE; INDAZOLE DERIVATIVE; TRKA PROTEIN, HUMAN;

ADULT; AGED; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; NEXT GENERATION SEQUENCING; NTRK1 GENE; PATIENT DERIVED TUMOR CELL LINE; PROSPECTIVE STUDY; PROTEIN EXPRESSION; STOMACH CANCER; TPM3 NTRK1 GENE; TUMOR CELL LINE; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; ENZYMOLOGY; GENETICS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TUMOR CELL CULTURE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BENZAMIDES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; INDAZOLES; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROSPECTIVE STUDIES; RECEPTOR, TRKA; TUMOR CELLS, CULTURED;

EID: 84948081268     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5494     Document Type: Article

References (19)

1. Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci. 2003; 4:299-309.
2. Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol. 2000; 10:381-391.
3. Pulciani S, Santos E, Lauver AV, Long LK, Aaronson SA, Barbacid M. Oncogenes in solid human tumours. Nature. 1982; 300:539-542.
4. Martin-Zanca D, Hughes SH, Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature. 1986; 319:743-748.
5. Greco A, Miranda C, Pagliardini S, Fusetti L, Bongarzone I, Pierotti MA. Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes. Genes Chromosomes Cancer. 1997; 19:112-123.
6. Greco A, Miranda C, Pierotti MA. Rearrangements of NTRK1 gene in papillary thyroid carcinoma. Mol Cell Endocrinol. 2010; 321:44-49.
7. Alberti L, Carniti C, Miranda C, Roccato E, Pierotti MA. RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol. 2003; 195:168-186.
8. Wiesner T, He J, Yelensky R, Esteve-Puig R, Botton T, Yeh I, Lipson D, Otto G, Brennan K, Murali R, Garrido M, Miller VA, Ross JS, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun. 2014; 5:3116.
9. Ross JS, Wang K, Gay L, Al-Rohil R, Rand JV, Jones DM, Lee HJ, Sheehan CE, Otto GA, Palmer G, Yelensky R, Lipson D, Morosini D, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014; 19:235-242.
10. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun. 2014; 5:4846.
11. Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y, Zhu X, Qu C, Chen X, Zhang J, Easton J, Edmonson M, Ma X, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014; 46:444-450.
12. Ricarte-Filho JC, Li S, Garcia-Rendueles ME, Montero-Conde C, Voza F, Knauf JA, Heguy A, Viale A, Bogdanova T, Thomas GA, Mason CE, Fagin JA. Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers. J Clin Invest. 2013; 123:4935-4944.
13. Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015; 5:25-34.
14. Lee J, Lee SE, Kang SY, Do IG, Lee S, Ha SY, Cho J, Kang WK, Jang J, Ou SH, Kim KM. Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer. 2013; 119:1627-1635.
15. Zheng Z, Liebers M, Zhelyazkova B, Cao Y, Panditi D, Lynch KD, Chen J, Robinson HE, Shim HS, Chmielecki J, Pao W, Engelman JA, Iafrate AJ, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 2014; 20:1479-1484.
16. Lee JY, Kim SY, Park C, Kim NK, Jang J, Park K, Yi JH, Hong M, Ahn T, Rath O, Schueler J, Kim ST, Do IG, et al. Patient-derived cell models as preclinical tools for genome-directed targeted therapy. Oncotarget. 2015; 6:25619-25630.
17. Lee DW, Choi YS, Seo YJ, Lee MY, Jeon SY, Ku B, Kim S, Yi SH, Nam DH. High-throughput screening (HTS) of anticancer drug efficacy on a micropillar/microwell chip platform. Anal Chem. 2014; 86:535-542.
18. Ardini E, Bosotti R, Borgia AL, De Ponti C, Somaschini A, Cammarota R, Amboldi N, Raddrizzani L, Milani A, Magnaghi P, Ballinari D, Casero D, Gasparri F, et al. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol. 2014; 8:1495-1507.
19. Filippo G, De Braud LP, Monica Niger, Silvia Damian, Benedetta Bardazza, Antonia Martinetti, Giuseppe Pelosi, Giovanna Marrapese, Laura Palmeri, Giulio Cerea, Emanuele Valtorta, Silvio Veronese, Andrea Sartore-Bianchi, Elena Ardini, Marcella Martignoni, Arturo Galvani, Paul Pearson, David Luo, James L. Freddo, Salvatore Siena. Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol. 2014; 32.